The Auckland based biotechnology company, Virionyx, is developing ground-breaking approached to infectious diseases, including a treatment for HIV.
They have successfully completed the US Federal Drug Agency's phase one clinical trials involving HIV positive volunteers, at Harvard Medical School Centre. There was early evidence of antiviral activity.
Virionyx now has the clearance for phase two trials to begin.
This is the first NZ developed biotheraputic to ever receive FDA clearance for clinical trials in the US.